TRAX
NASDAQFirst Tracks Biotherapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$34.48-1.97 (-5.40%)
01:30 PM07:45 PM
News · 26 weeks63+50%
2026-04-262026-10-18
Mix2990d
- Insider10(34%)
- Other8(28%)
- SEC Filings6(21%)
- Analyst4(14%)
- Offering1(3%)
Latest news
25 items- SECSEC Form 8-K filed by First Tracks Biotherapeutics Inc.8-K - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- PRFirst Tracks Biotherapeutics Announces $200 Million Private PlacementSAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 6,106,870 shares of its common stock to a limited group of institutional investors in a private placement at a price of $32.75 per share. First Tracks Biotherapeutics anticipates approximately $200 million in gross proceeds to the company before deducting placement agent fees and other expenses. Closing of the private placement is expected to occur on October 19, 202
- SECSEC Form 8-K filed by First Tracks Biotherapeutics Inc.8-K - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- PRFirst Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac DiseaseANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptomsLS mean change from baseline in Vh:Cd ratio of -0.17 on ANB033 vs. -0.66 on placebo, a +0.49 placebo-adjusted delta (p=0.009)LS mean change from baseline in IEL density of -1.20 on ANB033 vs. +18.83 on placebo, a -20.03 placebo-adjusted delta (p<0.001)Prevented an increase in symptoms throughout the entire gluten challenge, with lower CDSD score on ANB033 vs. placebo that was statistically significant from the first dayWell tolerated with no safety signals observed to dateConference call and webcast today, Monday, Oct. 12, 2026, at 8:30 a.m. ET to discu
- PRFirst Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT. A live webcast of the call will be available on the First Tracks website at: https://ir.firsttracksbio.com/news-events/events. The data will be provided in a
- ANALYSTCanaccord Genuity initiated coverage on First Tracks Biotherapeutics with a new price targetCanaccord Genuity initiated coverage of First Tracks Biotherapeutics with a rating of Buy and set a new price target of $50.00
- ANALYSTEvercore ISI initiated coverage on First Tracks Biotherapeutics with a new price targetEvercore ISI initiated coverage of First Tracks Biotherapeutics with a rating of Outperform and set a new price target of $65.00
- INSIDERDirector Orwin John A converted options into 1,300 shares, increasing direct ownership by 8% to 17,995 units (SEC Form 4)4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- ANALYSTGuggenheim initiated coverage on First Tracks Biotherapeutics with a new price targetGuggenheim initiated coverage of First Tracks Biotherapeutics with a rating of Buy and set a new price target of $100.00
- SECSEC Form 144 filed by First Tracks Biotherapeutics Inc.144 - First Tracks Biotherapeutics, Inc. (0002091349) (Subject)
- PRFirst Tracks Biotherapeutics Announces Participation in September Investor ConferencesSAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences: 21st Annual Wells Fargo Healthcare Conference, Boston Format – Fireside chat and one-on-one investor meetingsDate and Time – Wednesday, Sept. 9, 2026 at 9:30am ET / 6:30am PT Citi's 2026 Biopharma Back to School Conference, New York City Format – One-on-one investor meetingsDate and Time – Thursday, Sept. 10, 2026 Morgan
- INSIDERSEC Form 4 filed by Chief Business Officer Stone Benjamin4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERSEC Form 4 filed by President, CEO Faga Daniel4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Lizzul Paul F.4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- ANALYSTWolfe Research initiated coverage on First Tracks Biotherapeutics with a new price targetWolfe Research initiated coverage of First Tracks Biotherapeutics with a rating of Outperform and set a new price target of $83.00
- SECSEC Form SCHEDULE 13G filed by First Tracks Biotherapeutics Inc.SCHEDULE 13G - First Tracks Biotherapeutics, Inc. (0002091349) (Subject)
- SECSEC Form SCHEDULE 13G filed by First Tracks Biotherapeutics Inc.SCHEDULE 13G - First Tracks Biotherapeutics, Inc. (0002091349) (Subject)
- SECSEC Form 424B3 filed by First Tracks Biotherapeutics Inc.424B3 - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- SECSEC Form 10-Q filed by First Tracks Biotherapeutics Inc.10-Q - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- SECFirst Tracks Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- PRFirst Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business UpdateCompleted enrollment for Cohort 1 (gluten challenge) of Phase 1b ANB033 trial in celiac disease (CeD); top-line Cohort 1 data reaffirmed for Q4 2026Cohort 2 (mucosal healing) enhanced to enroll up to 40 patients including those with a broad range of histologic (Vh:Cd ratio ≤ 2.5) and symptom severity to further inform future development; top-line Cohort 2 data anticipated in Q1 2027U.S. FDA granted Fast Track designation for ANB033 for the treatment of CeDEnrollment ongoing for Phase 1b ANB033 trial in eosinophilic esophagitis (EoE); top-line data anticipated in Q3 2027Reiterating cash-runway into Q2 2028, including the expansion of ANB033 into two additional indications in H1 2027 SAN DIEG
- INSIDERAmendment: SEC Form 3 filed by new insider Lizzul Paul F.3/A - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Stone Benjamin3/A - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Faga Daniel3/A - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- SECSEC Form SCHEDULE 13G filed by First Tracks Biotherapeutics Inc.SCHEDULE 13G - First Tracks Biotherapeutics, Inc. (0002091349) (Subject)
TRAX FAQ
5 questionsWhere does TRAX stock trade?
First Tracks Biotherapeutics Inc. (TRAX) is listed on NASDAQ.What sector and industry is TRAX in?
First Tracks Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TRAX?
First Tracks Biotherapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-09-30. Recent price targets cluster around $3000.00.What companies are similar to TRAX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TRAX side-by-side with any of them on Quantisnow.How can I track TRAX on Quantisnow?
Quantisnow aggregates First Tracks Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TRAX to receive live email and push alerts on every new disclosure.